Publications
5803 Results
- Journal / Conference
- European Urology, Apr;79(4):446-452
- Year
- 2021
- Research Committee(s)
- Genitourinary
- PMID
- PMID33390282
- Study Number(s)
- JPR7
The Association Between Statin Use and Outcomes in Patients Initiating Androgen Deprivation Therapy
- Journal / Conference
- European Urology, Jan;79(1):16-19
- Year
- 2021
- Research Committee(s)
- Prevention, Screening, and and Surveillance
- PMID
- PMID33158661
- Study Number(s)
- S1823
Integrated Expression of Circulating miR375 and miR371 to Identify Teratoma and Active Germ Cell Malignancy Components in Malignant Germ Cell Tumors [Brief Correspondence based on S1823 Pilot]
- Journal / Conference
- Nature Reviews Urology, Jun 15;1-12
- Year
- 2021
- Research Committee(s)
- Genitourinary
- PMID
- PMID34131332
- PMC
- PMC8204595
- Study Number(s)
- SWOG-8507
100 years of Bacillus Calmette-Guérin immunotherapy: from cattle to COVID-19 [Review/Perspective]
- Journal / Conference
- Annals of Oncology, Sep;32(9):1077-1082
- Year
- 2021
- Research Committee(s)
- Breast
- PMID
- PMID34082017
- Study Number(s)
- S1007
Gene expression signatures for tailoring adjuvant chemotherapy of luminal breast cancer: stronger evidence, greater trust [Editorial]
- Journal / Conference
- Urologic Oncology, Apr;39(4):199-200
- Year
- 2021
- Research Committee(s)
- Genitourinary
- PMID
- PMID33487562
- Study Number(s)
- S1806
"Advancing bladder preservation: Biomarkers, decision-making, and therapy" [Review]
- Journal / Conference
- Journal for Immunotherapy of Cancer, Aug;9(8):e002973. doi: 10.1136/jitc-2021-002973
- Year
- 2021
- Research Committee(s)
- Lung
- PMID
- PMID34429332
- PMC
- PMC8386207
- Study Number(s)
- S1400F
Phase II Study of Durvalumab Plus Tremelimumab as Therapy for Patients with Previously Treated Anti-PD-1/PD-L1 Resistant Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study S1400F, NCT03373760)
- Journal / Conference
- Blood, Aug 18;blood.2020010146. doi: 10.1182/blood.2020010146. Online ahead of print.
- Year
- 2021
- Research Committee(s)
- Leukemia
- PMID
- PMID34407545
- PMC
- PMC8718628
- Study Number(s)
- CTSU/E1912
Measurable Residual Disease Does Not Preclude Prolonged Progression-free Survival in CLL Treated with Ibrutinib
- Journal / Conference
- European Urology, Mar;79(3):e85-e86
- Year
- 2021
- Research Committee(s)
- Prevention, Screening, and and Surveillance
- PMID
- PMID33357996
- Study Number(s)
- S1823
Reply to John T. Lafin, Aditya Bagrodia’s Letter to theEditor re: Lucia Nappi, Marisa Thi, Nabil Adra, et al.Integrated Expression of Circulating miR375 andmiR371 to Identify Teratoma and Active Germ Cell Malignancy Components in Malignant Germ Cell Tumors. Eur Urol 2021;79:16–9
- Journal / Conference
- Cancer, Oct 15; 127(20):3717-3719
- Year
- 2021
- Research Committee(s)
- Gastrointestinal
- PMID
- PMID34374076
- Study Number(s)
- CTSU/C80405
Clinical trials as a path toward equity [Editorial]
- Journal / Conference
- Cancer Epidemiology, Biomarkers & Prevention, Apr;30(4):669-675
- Year
- 2021
- Research Committee(s)
- Cancer Care Delivery
- PMID
- PMID33355237
- PMC
- PMC8026561